PRACTICAL GUIDE | 2026

The Two-Country FIH Strategy: De-risking Timelines and Enrollment with Parallel Programs

One country is a plan. Two countries are insurance.

By Julio G. Martinez-Clark

CEO, bioaccess®

Last verified: September 2026 | General information only—not legal or regulatory advice. Rules change frequently; confirm the strategy with qualified regulatory counsel.

Publishing package

FIH is first-in-human: the first time a device or drug is tested in people. A two-country FIH strategy does not mean running the same study twice. It means designing one program with staged, sequential cohorts across two countries in Latin America — early cohorts enrolling in the faster-activating market while the second market completes startup, with each cohort's safety data reviewed before the next begins. The two-country FIH strategy is timeline insurance: if one country's startup stalls or enrollment underperforms, the program still moves.

This is a design framework, not a promise about any specific pair of countries. Every pairing below is illustrative — an example of how the selection logic works, not a guaranteed outcome. The right pair depends on your device, your indication, and the feasibility data.

How does a staged two-country program actually work?

The architecture is sequential cohorts, parallel infrastructure:

1. Country A activates first. Typically a fast-corridor market — Panama, El Salvador, Chile, or Costa Rica — where ethics and regulator submissions run in parallel and activation is measured in weeks. Early cohorts enroll here.
2. Country B starts up in parallel. A larger market — Brazil, Mexico, Colombia, or Argentina — with deeper investigator benches and larger patient populations, on its longer startup clock. Its sites come online as later cohorts begin.
3. Safety gates between cohorts. Each cohort's safety data is reviewed independently before the next cohort enrolls, regardless of which country hosts it. The safety review is per-cohort, not per-country.
4. Enrollment flexes to reality. If Country A enrolls faster than modeled, later cohorts can expand there. If it underperforms, Country B's sites absorb the load. The program is no longer hostage to a single site's patient flow.

Note what this is not: it is not two independent studies, and it is not a way to dodge safety oversight. One protocol, one safety standard, two (or more) national regulatory pathways executed in parallel.

How do you choose the country pair?

Pair selection is the whole game. The framework bioaccess® uses weighs six criteria — and the answer is almost never 'the two fastest countries':

Selection criterion	What to evaluate	Why it matters
Activation speed	Weeks-to-activation by pathway: fast corridor (weeks) vs. major markets (months).	Determines which country hosts the early cohorts.
Patient flow for your indication	Real site-level flow, not national population. Small countries can starve a program; large countries with the wrong referral patterns can too.	Enrollment is the risk you are insuring against.
Investigator depth	Number of qualified investigators and backup sites per country.	One brilliant investigator is a single point of failure.
Perceived data rigor	How regulators and future partners view data from each market. Brazil, Argentina, Mexico, Colombia, and Chile generally sit in the top tier.	Matters when the FIH data must support FDA or partner discussions.
Cost tier	Site and hospital fees vary widely — hospital fees in El Salvador, for example, run well below Panama's.	A fast country that breaks the budget is not fast.
Import and startup mechanics	Import-permit lead times, IOR requirements, translation burden.	Two countries means two import workstreams; plan both from day one.

What do illustrative pairings look like?

These are design examples showing how the criteria combine — not recommendations for your study and not guaranteed outcomes:

• Fast corridor + major market. Early cohorts in a fast-activating country (Panama, El Salvador) while a larger market (Brazil, Colombia) completes startup for later cohorts. Speed now, scale and data-rigor perception later.
• Fast corridor + backup. Primary enrollment in one fast country with a second fast country on standby — for example, Panama primary with El Salvador or Chile ready to activate. Lower startup cost than a major-market pairing; less enrollment depth.
• Major market + major market. For programs that need enrollment volume from day one and can fund two full startup tracks. Maximum enrollment insurance, maximum cost.

The pattern: one country buys speed, the other buys depth, redundancy, or perception. If both countries in your pair serve the same purpose, you have not designed a strategy — you have duplicated a budget.

What does the two-country FIH strategy cost — and what does it buy?

Honest accounting. A second country roughly duplicates the startup-phase costs: a second ethics and regulatory filing, a second import-permit workstream, additional site qualification, translation, and CRO startup fees. It does not duplicate the per-patient economics — you are still enrolling the same total cohort; you are buying a second place to enroll them.

What that buys: the two-country FIH strategy converts the two largest FIH schedule risks — a stalled approval and a dry enrollment pipeline — from program-killers into manageable variances. For a venture-backed sponsor whose runway is measured in months, that insurance is frequently cheaper than the delay it prevents. For a well-funded sponsor with a common indication and proven sites, it may be unnecessary. The feasibility data should make the call, not the ambition.

When should you NOT go multi-country?

• The indication enrolls easily and one country's feasibility numbers are strong — redundancy without risk is overhead.
• The budget cannot absorb two startup tracks without cutting corners on monitoring or data quality. Never fund the second country by thinning the first.
• The device or protocol is still changing. Multi-country startup multiplies the cost of every amendment.
• No feasibility work has been done in either country. Two unvalidated countries are not diversification; they are two guesses.

Design checklist: the two-country FIH strategy done right

1. Run feasibility in both countries before committing. Test two to three countries; let site-level patient flow and startup clocks — not enthusiasm — pick the pair.
2. Assign each country a job. Speed, depth, redundancy, perception: if a country has no defined role, cut it.
3. Stage the cohorts with safety gates. Sequential cohorts, independent safety review between them, regardless of which country hosts each cohort.
4. Run both startup tracks in parallel. A backup country that starts up after the primary fails is not a backup; it is a rescue mission.
5. Budget the full second startup. Two filings, two import workstreams, two site qualifications. Price it honestly or do not do it.
6. Keep one protocol and one data standard. ICH-GCP (International Council for Harmonisation Good Clinical Practice) data from qualified sites is what makes multi-country FIH data usable downstream — including for FDA discussions.

Frequently asked questions

Does a two-country FIH study mean double the patients?

No. The total cohort is the same; it is distributed across the two countries' sites. You are buying a second enrollment engine and a second regulatory pathway, not a second study.

Which country should enroll the first cohort?

Usually the faster-activating one, so first-patient-in is not hostage to the slower market's startup clock. The slower market's sites join for later cohorts once activated.

Will the FDA accept FIH data from two Latin American countries?

FDA acceptance turns on ICH-GCP compliance and qualified sites and investigators — not on the number of countries. Multi-country data generated to one protocol and one standard is routinely usable; see our post on FDA acceptance of LATAM FIH data.

How much more does the two-country FIH strategy cost?

Roughly a duplicated startup track: second ethics/regulatory filing, second import workstream, added site qualification and translation. Per-patient costs do not double. The honest comparison is against the cost of a multi-month delay.

Can we add the second country later if the first one stalls?

You can, but a country added in panic starts its clock at zero — months behind. The insurance value comes from running both startup tracks in parallel from the beginning.

Is a two-country strategy the same as a backup site?

No. A backup site is redundancy within one regulatory pathway. A second country is redundancy across regulatory pathways — it protects against approval delays and country-level enrollment failure, which no backup site can fix.

Design the program before you commit to the countries

The two-country FIH strategy is a program-design decision, not a reaction to a stalled startup. bioaccess® builds staged multi-country FIH programs across Latin America — feasibility in two to three markets, parallel startup tracks, sequential cohorts with independent safety review — so your timeline survives contact with reality.

Talk with bioaccess® about your Latin America FIH strategy

Regulatory references

• ICH E6 Good Clinical Practice (GCP) — the data standard underlying multi-country FIH programs.
• bioaccess® blog: Will the FDA Accept Data from a Latin American First-in-Human Trial? (2026).
• bioaccess® blog: How Long Does It Take to Start a First-in-Human Trial in Latin America? A Country-by-Country Startup Clock (2026).
• bioaccess® blog: El Salvador, Panama, Chile, Costa Rica: Inside Latin America's Fast-Track FIH Corridor (2026).
• bioaccess® blog: Patient Recruitment for FIH Trials in Latin America: What the Feasibility Numbers Actually Look Like (2026).